OPEN MIC NEXT IN BIOTECH SERIES – Growing from early stage to mature company

Date

20.06.2023 17:30 - 19:00

Application date

13.06.2023

Location

MC - Main Campus Meeting Center, Hegenheimermattweg 167D, 4123 Allschwil

Register

Follow this Link

Are you about to take the leap into the world of biotech entrepreneurship as you spin off from academia? Then our very first Open Mic Next in Biotech Series on growing from early stage to mature company is exactly where you want to be.

Experts at this event will discuss the different stages of growth and the pitfalls that come with each stage. From a startup incubator to companies at different stages of growth to a venture capital firm – our guests share their experiences and shed light on what helps with growth and development.

On this occasion, we will:

Discover key factors for transitioning to industry settings
Emphasize the importance of finding independent space
Explore essential considerations for partnerships and funding
Navigate the growth phases and learn how to overcome associated challenges
Trace the evolutionary journey: from startup incubator to established companies to venture capital firms
Gain insights from guest speakers, drawing from their growth and development experiences Following our successful series in healthcare, we introduce our biotech focussed series of events at our site Main Campus.

Meet the expert panel:

Sascha-Oliver Bucher, co-founding Partner Forty51 Ventures
Dr. Stephan Emmerth, Director of Therapeutic Innovation and BaseLaunch
Dr. Torsten Hoffmann, Senior Drug Discovery Consultant and Board Member
Dr. Simon Ittig, CEO and Co-founder of T3 Pharmaceuticals AG
The session will be moderated by Sarah Holland, President of Swiss Healthcare Licensing Group.

Participation is free, however, registration is required before 13.06.2023 (on-site).

Principal

Directory of active investors

Our directory of active investors includes more than 200 VCs and other institutional investors who invested in Swiss start-ups in the last years. Each profile has links to the news mentioning the investors, so that it is possible to check which companies received the money and what they are doing, how often the VC invests and who are the preferred co-investors.